Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 18 chart positions in 18 markets.
By chart position
- 🇨🇦CA · Life Sciences#35100K to 300K
- 🇬🇧GB · Life Sciences#1945K to 30K
- 🇯🇵JP · Life Sciences#3630K to 100K
- 🇰🇷KR · Life Sciences#6710K to 30K
- 🇳🇱NL · Life Sciences#7610K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
120K to 396K🎙 ~2x weekly·87 episodes·Last published 2w ago - Monthly Reach
Unique listeners across all episodes (30 days)
239K to 792K🇨🇦38%🇯🇵13%🇫🇮13%+15 more - Active Followers
Loyal subscribers who consistently listen
96K to 317K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHosts
Recent guests
Recent episodes
Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D
Jun 9, 2026
53m 59s
Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating
May 12, 2026
47m 23s
Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design
Apr 15, 2026
38m 49s
Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement
Mar 17, 2026
58m 44s
Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?
Feb 10, 2026
49m 08s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/9/26 |  Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D✨ | AI in biotherapeuticsmachine learning+3 | Andrew Buchanan, Ph.D.Norbert Furtmann, Ph.D. | University of MichiganSanofi | — | AImachine learning+5 | — | 53m 59s | |
| 5/12/26 |  Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating✨ | drug discoveryprotein engineering+4 | Daniel Chen | Synthetic Design Lab | — | drug discoveryprotein engineering+4 | — | 47m 23s | |
| 4/15/26 |  Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design✨ | protein designautomated pipeline+3 | Martin Pacesa | BindCraftUniversity of Zurich | — | BindCraftprotein binder design+3 | — | 38m 49s | |
| 3/17/26 |  Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement✨ | T cell engagementimmune cell engagement+3 | Patrick BaeuerleJeffrey Miller | Cullinan TherapeuticsMasonic Cancer Center | — | T cellimmune cell+6 | — | 58m 44s | |
| 2/10/26 |  Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?✨ | biologic therapeuticsmonoclonal antibodies+3 | Paul CarterG. Jonah Rainey+1 | GenentechEli Lilly and Company+1 | — | biologicstherapeutics+5 | — | 49m 08s | |
| 1/13/26 |  Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research✨ | cancer immunotherapyresearch evolution+4 | Laszlo Radvanyi | University of TorontoMD Anderson | — | immunotherapycancer+5 | — | 44m 15s | |
| 12/9/25 |  Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity✨ | immunogenicitybiologic molecules+4 | Vibha Jawa | EpiVax | — | immunogenicitybiologic molecules+5 | — | 26m 58s | |
| 11/11/25 |  Episode: 79 - Conversation with Bahija Jallal on the Biggest Anticipated Transformations and Breakthroughs✨ | T-cell engagersdrug discovery+3 | Bahija Jallal | Immunocore | — | T-cell engagersdrug development+3 | — | 42m 46s | |
| 10/14/25 |  Episode: 78 - Shamit Shrivastava on an Interdisciplinary Approach to Antibody Biophysics and Developability✨ | antibody biophysicsdrug development+3 | Shamit Shrivastava | Apoha | — | antibodybiophysics+4 | — | 33m 31s | |
| 9/16/25 |  Episode: 77 - Derek Lowe on AI and the US Biotech Ecosystem✨ | AI in drug discoverybiotech ecosystem+3 | Derek Lowe | NovartisAI Proteins | — | AIdrug discovery+5 | — | 42m 25s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 8/12/25 |  Alexey Lugovskoy Shares Decades of Experience in Starting Out and Founding Companies✨ | protein engineeringentrepreneurship+3 | Alexey Lugovskoy | Diagonal Therapeutics | Soviet Union | protein engineeringDiagonal Therapeutics+3 | — | 47m 23s | |
| 7/29/25 |  Episode: 75 - Are Licensing Fees Required or Gatekeeping? | July 15, 2025 | Are licensing fees required or gatekeeping? In this episode of The Chain, host Nimish Gera, vice president of Biologics at Mythic Therapeutics, and Ian Wilkinson, CEO of Gamma Proteins, discuss accessing antibody discovery technology through licensing fees and royalties—and whether these fees are justified or not. Wilkinson delves into the current landscape of antibody discovery technologies, including if AI-based technology warrants fees, how royalties affect both small compa... | 32m 30s | ||||||
| 6/11/25 |  Episode: 74 - Keith Flaherty, President-Elect of AACR, on Public and Private Collabs, AI Optimism, and More | June 10, 2025 | In this bonus episode of The Chain, Daniel Chen, MD, PhD, founder and CEO of Synthetic Design Lab, returns for the Science Commune segment and speaks with Keith Flaherty, MD, FAACR, professor of Medicine of Harvard Medical School and president-elect of AACR. They discuss Flaherty’s prolific career; how his background led him to pursue a career in medicine; how public and private sectors are coming together in oncology around collaborations; reflections on targeted therapies an... | 47m 23s | ||||||
| 6/10/25 |  Episode: 73 - PANEL DISCUSSION: Near-Term Challenges for AI/ML in Biotherapeutic R&D | June 10, 2025 | This episode of The Chain features a panel discussion from May’s PEGS Boston. Moderated by Peter Tessier, Albert M. Mattocks professor of Pharmaceutical Sciences and Chemical Engineering at the University of Michigan, the panelists include Sarel Fleishman, professor of Biomolecular Sciences at the Weizmann Institute of Science; Kadina Johnston, senior specialist of Discovery Biologics at Merck & Co.; Vincent Ling, chief business officer of Morphocell Technologies; Arvind R... | 1h 01m 21s | ||||||
| 5/13/25 |  Episode: 72 - Pamela Barney on HR Lessons to Meet the Needs of Biotech | In this episode of The Chain, host Tariq Ghayur, PhD, Tariq Ghayur Consulting, LLC, talks with Pamela Barney, former associate director of HR, AbbVie, about her career within biotech/pharma organizations and some key lessons learned, such as taking advantage of your contacts and network, managing diverse workforces, and HR’s role in creating an engaged team. Barney also discusses why she entered the HR field and the challenges of culture changes when transitioning from a small organization to... | 35m 23s | ||||||
| 4/15/25 |  PEGS Young Scientist Keynote Jessica Stark on the Role of Glycans in Cancer Research | In this episode of The Chain, host Brandon DeKosky, associate professor, speaks with MIT colleague Jessica Stark, Underwood-Prescott career development professor, about glycans and why they are important in cancer research. Stark discusses how she became interested in immunology, what her PhD and post-doctoral training was like, her thoughts on singlets operating as part of a network of checkpoint molecules, and what’s currently going on in glycobiology. She also talks about her keynote prese... | 28m 38s | ||||||
| 3/12/25 |  Episode: 70 - Views on Machine Learning and AI in the Antibody and Protein Engineering Space | March 11, 2025 | In this episode of The Chain, host Andrew Buchanan, principal scientist at AstraZeneca, and Andreas Plückthun, professor and head of biochemistry at the University of Zurich, discuss AI/ML technologies in the antibody and protein engineering space. Plückthun shares his perspectives on what technologies show promise and success, why the definition of epitope is important when developing a drug, and what aspects he expects to improve in the ML field in the future. | 49m 36s | ||||||
| 2/21/25 |  Episode: 69 - Conversation with Sir Greg Winter on the 50th Anniversary of the Milstein and Köhler Paper | February 21, 2025 | This episode marks the 50th anniversary of one of the most influential papers in biomedical science—the 1975 Milstein and Köhler paper on hybridoma technology, which paved the way for monoclonal antibodies. Ralph Minter, Biotech CSO/CTO, discusses this important milestone with a true pioneer in the field, Sir Greg Winter, Nobel Laureate and one of the key figures in the development of therapeutic antibodies. | 50m 36s | ||||||
| 12/10/24 |  Episode: 68 - Changing the Game of Protein-Protein Interactions With Randolph Lopez | In this episode of The Chain, host Andrew Bradbury, CSO of Specifica, an IQVIA business, speaks with Randolph Lopez, CTO and co-founder of A-Alpha Bio, about how A-Alpha Bio is changing the game of protein-protein interactions with their platform AlphaSeq. Lopez delves into the origins, the process, the successes, and the possibilities of the company’s platform and how it can help with epitope mapping, affinity predictions, and off-target binding. With the data the platform generates, Lopez a... | 46m 00s | ||||||
| 11/12/24 |  Episode: 67 - Anthony Tolcher Discusses Oncology, Dual-Payload Technology, and the ADC Field | November 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload technologies, the potency of new payloads, and bispecific targeting. Tolcher also shares what inspired him to pursue oncology, how he came across ADCs,... | 42m 34s | ||||||
| 10/16/24 |  Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond | October 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more successful now compared to in the past, and where he sees ADCs going forward. He also discusses his thoughts on the half-life of diffusible payloads, the ... | 39m 43s | ||||||
| 9/10/24 |  Episode 65- Tariq Ghayur on the Renaissance of Bispecifics and ADCs, AI, and More | September 10, 2024 | In this episode of The Chain, host Nimish Gera speaks with Tariq Ghayur, of Tariq Ghayur Consulting, LLC and Entrepreneur in Residence, FairJourney Biologics (and a fellow host of the podcast), about the current renaissance of bispecifics and ADCs, the impact of AI in pharmaceuticals, and what to watch out for in the biopharma space in the next few years. Ghayur also shares his journey from BASF Pharma to AbbVie, what it was like when the industry shifted its focus from s... | 31m 55s | ||||||
| 8/13/24 |  Episode: 64 - Peyton Greenside on AI’s Role in Antibody Engineering, Optimization, and More | In this episode of The Chain, host Nimish Gera, Ph.D., vice president of biologics at Mythic Therapeutics, speaks with Peyton Greenside, CSO and co-founder of BigHat Biosciences, about the role of AI and machine learning in antibody engineering and targeting complex modalities, including bispecifics and ADCs. Greenside also discusses the work her organization does, what BigHat is doing to ensure the quality of data to train their AI models with, the methods of approaching harder targets such ... | 32m 31s | ||||||
| 7/16/24 |  Episode: 63 - Discussing Protein Signaling and Structural Biology With Andrew Kruse | In this episode of The Chain, host Brandon DeKosky, associate professor at MIT, speaks with Andrew Kruse, PhD, professor of biological chemistry and molecular pharmacology at Harvard University, about protein signaling and structural biology. Kruse explains what exactly bias signaling is and discusses the problems he and his team are working to resolve, as well as the tools they use to work out the dynamics of structures. He also shares the findings in signaling receptors and biology that he’... | 38m 18s | ||||||
| 6/11/24 |  Episode: 62 - AI/ML in Antibody Discovery and Engineering: Reality, Hope, Future, and Hype | his special episode of The Chain features a panel of industry experts who discussed AI and ML in antibody discovery and engineering at this year’s PEGS Boston event. Peter Tessier, professor at the University of Michigan; Andrew Bradbury, CSO at Specifica; Andrew Waight, Senior Director of Machine Learning, Discovery Biologics & Protein Sciences at Merck Research Labs; Peyton Greenside, Co-Founder & CSO of BigHat Biosciences; and Paolo Marcatili, Director of Antibody Design at Novo No... | 1h 03m 57s | ||||||
Showing 25 of 89
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
20 placements across 18 markets.
Chart Positions
20 placements across 18 markets.